Which Diabetes Drugs Best Treat Fatty Liver Disease? Network Meta-Analysis Ranks Them | Research

The takeaway

A network meta-analysis found GLP-1 RAs and pioglitazone most effective for MASH histological improvement, with weight loss mediating a significant portion of the fibrosis benefit.

GLP-1 RAs top ranked
Most effective anti-diabetic agents for biopsy-confirmed MASH fibrosis improvement

What the researchers found

GLP-1 RAs and pioglitazone showed the greatest histological improvement in MASH, with weight loss mediating a significant portion of fibrosis benefit.

Why it matters

MASH is becoming a leading cause of liver transplantation. Identifying which diabetes drugs best improve liver histology could prevent progression to cirrhosis in millions.

How the study worked

Frequentist random-effects network meta-analysis of biopsy-confirmed MASH trials; primary outcome: fibrosis improvement; dose-response and weight loss mediation analyzed.

What this study cannot tell us

Network meta-analysis relies on indirect comparisons; included trials had varying durations and populations; biopsy-based outcomes have sampling variability.

How to read the evidence

Network meta-analysis of biopsy-confirmed trials — strong methodology for comparing therapies without head-to-head data.

When this study was published

Published 2026 in Diabetes, Obesity & Metabolism.

The bigger picture

This establishes GLP-1 RAs as leading MASH therapies, potentially rivaling or complementing dedicated MASH drugs like resmetirom.

Questions still open

Should GLP-1 RAs be used specifically for MASH prevention in diabetic patients?
How does tirzepatide compare to semaglutide for MASH fibrosis improvement?

Common questions

Can diabetes drugs treat fatty liver disease?

Yes — this analysis found GLP-1 drugs and pioglitazone were most effective at improving liver damage in biopsy-confirmed MASH, with higher doses producing greater benefit.

Is the liver benefit from the drugs themselves or from weight loss?

Both — while weight loss mediated a significant portion of fibrosis improvement, the drugs also appear to have direct liver benefits beyond what weight loss alone explains.

Read the original research

Histological efficacy of anti-diabetic agents in MASH and the mediating role of weight loss: A network meta-analysis.

Diabetes, obesity & metabolism, 28(1), 287-295

View on PubMed ↗Publisher’s paper ↗

Citation

Banerjee, Mainak; Pal, Rimesh; Pal, Sandip. (2026). Histological efficacy of anti-diabetic agents in MASH and the mediating role of weight loss: A network meta-analysis.. Diabetes, obesity & metabolism, 28(1), 287-295. https://doi.org/10.1111/dom.70187